<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886297</url>
  </required_header>
  <id_info>
    <org_study_id>lwh87331597</org_study_id>
    <nct_id>NCT04886297</nct_id>
  </id_info>
  <brief_title>A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder</brief_title>
  <official_title>Department of Nutrition and Food Hygiene,School of Public Health, Sun Yat-sen University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to study the effect of resveratrol on the improvement of lipid metabolism,&#xD;
      randomized intervention trials were conducted to compare the effects of resveratrol on the&#xD;
      improvement of lipid metabolism in different dose groups. To explore the best dose of&#xD;
      resveratrol for the prevention and treatment of metabolic diseases provide an important&#xD;
      scientific basis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to study the effect of resveratrol on the improvement of lipid metabolism,&#xD;
      randomized controlled trials were conducted to enrolled 160 patients with dyslipidemia. The&#xD;
      subjects were divided into 0 mg / d, 100 mg / d, 300 mg / d, 600 mg/ d four dose groups,&#xD;
      intervention for 8 weeks, comparing different doses of resveratrol on lipid metabolism. To&#xD;
      explore the best dose of resveratrol for the prevention and treatment of metabolic diseases&#xD;
      provide an important scientific basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of resveratrol on blood lipid index in patients with dyslipidemia</measure>
    <time_frame>Change from Baseline Blood Lipid Index at 4 weeks and 6 weeks</time_frame>
    <description>Lipid index in serum will be measured, mainly including TC, TG, LDL-C and HDL-C, by the enzymic method and direct method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of resveratrol on cholesterol efflux capacity in patients with dyslipidemia</measure>
    <time_frame>Change from Cholesterol Efflux Capacity at 4 weeks and 6 weeks</time_frame>
    <description>Cholesterol efflux capacity will be measured by measuring the efflux of fluorescencelabeled cholesterol from J774 macrophages to apolipoprotein B-depleted plasma of study subjects.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo capsules only contained pullulan and maltodextrin. During the trial period, the participants were instructed to consume two Mega Resveratrol® placebo capsules once daily (30 min after breakfast).&#xD;
Intervention: Drug: Mega Resveratrol® capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg/d resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (100 mg anthocyanins per capsule) will provid a total daily intake of 100 mg resveratrol.&#xD;
Intervention: Drug: Mega Resveratrol® capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300mg/d resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule) will provid a total daily intake of 300 mg resveratrol.&#xD;
Intervention: Drug: Mega Resveratrol® capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600mg/d resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the trial period, the participants will be instructed to consume two Mega Resveratrol® capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule, 2 per day) will provid a total daily intake of 600 mg resveratrol.&#xD;
Intervention: Drug: Mega Resveratrol® capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mega Resveratrol® capsules</intervention_name>
    <description>Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.</description>
    <arm_group_label>100mg/d resveratrol</arm_group_label>
    <arm_group_label>300mg/d resveratrol</arm_group_label>
    <arm_group_label>600mg/d resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mega Resveratrol® Placebo capsules</intervention_name>
    <description>Mega Resveratrol® Placebo capsules</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dyslipidemia&#xD;
&#xD;
          -  The age between 35 and 70 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intake of any medicine that affect lipid metabolism currently or in the preceding 6&#xD;
             months&#xD;
&#xD;
          -  Dietary supplementation with phytochemicals including resveratrol in the preceding 3&#xD;
             months&#xD;
&#xD;
          -  History of acute or chronic infectious disease, autoimmune disease, cancer, traumatic&#xD;
             injury, or surgery in the preceding 1 month&#xD;
&#xD;
          -  History of severe chronic disease including AS and CVD, liver or renal dysfunction,&#xD;
             and lactation or pregnancy&#xD;
&#xD;
          -  Pregnant woman and Breast Feeding Women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Wenhua</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Campus, Guangzhou Campus, No. 74, Zhongshan 2nd Road, Yuexiu District, Guangzhou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhou Yuqing</last_name>
    <phone>15622126860</phone>
    <email>1147317854@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou Yuqing</last_name>
      <phone>15622126860</phone>
      <email>1147317854@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhou Yuqing</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

